Journal of Clinical and Experimental Ophthalmology
Open Access

Iris V Vizzuett-Lopez

Publications

• Research Article
  Safety and Efficacy of Topical 0.1% And 0.05% Cyclosporine A in an Aqueous Solution in Steroid-Dependent Vernal Keratoconjunctivitis in a Population of Mexican Children
  Author(s): Leopoldo M Baiza-Duran, Ana C González-Villegas, Yussett Contreras-Rubio, Juan C Juarez-Echenique, Iris V Vizzuett-Lopez, Raul Suarez-Sanchez, Concepcion Santacruz-Valdes, Jose F Alaniz-de-la-O and Laura R Saucedo-RodriguezLeopoldo M Baiza-Duran, Ana C González-Villegas, Yussett Contreras-Rubio, Juan C Juarez-Echenique, Iris V Vizzuett-Lopez, Raul Suarez-Sanchez, Concepcion Santacruz-Valdes, Jose F Alaniz-de-la-O and Laura R Saucedo-Rodriguez
  
  Purpose: Evaluate safety, efficacy and tolerability of 0.1% and 0.05% Cyclosporine A eye drops in Mexican children with Steroid Dependent Vernal Keratoconjunctivitis. Methods: This was a multicenter, prospective, randomized and double masked clinical trial where the effects of 0.1 and 0.05% cyclosporine A (aqueous solution) eyedrops were evaluated in children with steroid dependent Vernal Keratoconjunctivitis. Patient evaluation was done at baseline, 2, 7, 14, 30, 60, 90, 120, 150, and 180 days. Conjunctival discharge, conjunctival papillae size, conjunctival chemosis, tearing, itching, burning sensation, photophobia and conjunctival hyperemia were the primary endpoints. Results: 112 patients (224 eyes) with Vernal Keratoconjunctivitis were included (mean age=10.25 ± 3.83 years). 56 patients received 0.1% Cyclospori.. View More»
  DOI: 10.4172/2155-9570.1000115

  Abstract PDF

Relevant Topics